Studies
Every study, review and regulatory document in the collection, newest first. Each links to a page with its population, findings, funding and original source.
01Find
Filter studies
10 studies · Download as JSON
- Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trialRandomized trial · 2026 · Study tier 3 · Different population · Benefit
- Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trialRandomized trial · 2026 · Study tier 2 · Different population · Benefit · Industry funded
- Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trialRandomized trial · 2026 · Study tier 1 · Different population · Mixed · Industry funded
- Positive modulation of glucagon-like peptide 1 (GLP-1) receptor by endogenous haemorphins with implications in glucose metabolism and diabetesAnimal study · 2026 · Facts auto-extracted
- Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysisMeta-analysis · 2026 · Study tier 2 · Different population · Benefit
- Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoringPharmacovigilance · 2026 · Facts auto-extracted
- Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic ReviewSystematic review · 2026 · Facts auto-extracted
- Reported cardiovascular events and cardiometabolic risk markers with orforglipron and danuglipron in adults with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized trialsMeta-analysis · 2026 · Not yet reviewed
- Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trialsMeta-analysis · 2026 · Study tier 2 · Different population · Harm direction
- Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetesRandomized trial · 2025 · Facts auto-extracted